|
End-of-day quote
Shanghai S.E.
2026-08-19
|
5-day change | 1st Jan Change | ||
| 17.91 CNY | 0.00% |
|
-1.27% | +1.65% |
| Apr. 24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
| Apr. 24 | Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4% | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 20,397 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | 1.65% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 16,878 | 16,387 | 15,979 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | 0.28% | -2.91% | -2.49% |
| P/E | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 13.7x | 11.9x | 10.4x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.57x | 2.36x | 2.18x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.7x | 0.8x | 0.7x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.68x | 0.62x | 0.56x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.56x | 0.5x | 0.44x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 4.49x | 3.85x | 3.33x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 7.41x | 6.25x | 5.34x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 16.7x | 8.02x | 6.53x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 5.98% | 12.5% | 15.3% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.9007 | 0.993 | 1.181 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 5.03% | 5.54% | 6.59% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.304 | 1.505 | 1.717 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 69.1% | 66% | 68.8% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,906 | 33,032 | 36,680 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,761 | 4,251 | 4,791 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,278 | 2,621 | 2,993 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,485 | 1,714 | 1,954 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,519 | -4,010 | -4,418 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 17.91 | 17.91 | 17.91 |
| Nbr of stocks (in thousands) | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,848 | - | - |
| Announcement Date | 4/27/22 | 4/27/23 | 4/28/24 | 4/25/25 | 4/23/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.74x | 0.56x | 4.49x | 5.03% | 3.02B | |
| 17.64x | 0.74x | 11x | -.--% | 15.65B | |
| 21.75x | 0.84x | 14.18x | 1.03% | 6.71B | |
| 16.11x | 0.73x | 7.62x | 2.31% | 6.13B | |
| 14.99x | 0.98x | 7.09x | 2.82% | 4.31B | |
| 14.46x | 1.24x | 7.59x | 5.56% | 3.22B | |
| 14.43x | 0.87x | 6.54x | 4.44% | 3.01B | |
| 31.19x | - | - | - | 2.42B | |
| 20.91x | 0.61x | 7.78x | 1.96% | 1.55B | |
| Average | 18.36x | 0.82x | 8.29x | 2.9% | 5.11B | |
| Weighted average by Cap. | 17.92x | 0.81x | 9.50x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
